Santhera Pharmaceuticals Holding AG
Save
86.41M
Market cap
1.46x
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies.
Similar securities
Based on sector and market capitalization
Report issue